Cession Oncology is a late preclinical-stage biotechnology company advancing cutting-edge therapies to transform the treatment of pancreatic cancer and other deadly cancers.
Our proprietary nanoparticle technology, developed at Georgetown University Medical Center, has shown a remarkable ability to inhibit primary tumor growth and completely halt metastasis in pancreatic cancer models.
We’ve built a world-class team with deep expertise spanning academia, industry, and investment.
Company Details
- Employees
- 2
- Founded
- 2025
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cessiononcology.com
- Keywords
- Health and Human Services.
Cession Oncology Questions
Cession Oncology's website is http://www.cessiononcology.com
Cession Oncology's LinkedIn profile is https://www.linkedin.com/company/cessiononcology
Cession Oncology has
2 employees.
View email and phone details for 2
employees at Cession Oncology.
Cession Oncology's industry is
Biotechnology Research
Cession Oncology's top competitors are
Amrok,
Medical Ingenuities,
Oboro Labs Inc.,
Smarttracker Solutions For Health & Human Services,
Vectgen Biosciences,
Syp,
Circuitry.ai,
Bounceback Pickle,
Synmatter,
Solas Bioventures.
Cession Oncology's categories are Biotechnology Research
Cession Oncology's founding year is 2025
